Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Piotr Kuna, Marek Jutel, Grazyna Pulka, Slawomir Tokarski, Paula Arranz, Gonzalo Hernández & Nieves Fernández Hernando. (2023) Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study. Clinical Ophthalmology 17, pages 735-746.
Read now
Read now
David Clark, Paul Karpecki, Anne Marie Salapatek, John D Sheppard & Todd C Brady. (2022) Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure. Clinical Ophthalmology 16, pages 15-23.
Read now
Read now
Megan E Cavet, Paul J Gomes, Warner W Carr & Jon I Williams. (2018) Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. Journal of Asthma and Allergy 11, pages 29-39.
Read now
Read now
Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul Gomes & Gail Torkildsen. (2017) Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical Ophthalmology 11, pages 1089-1097.
Read now
Read now
Edward Meier, Abhijit Narvekar, Ganesh R Iyer, Harvey B DuBiner, Apinya Vutikullird, David Wirta & Kenneth Sall. (2017) Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clinical Ophthalmology 11, pages 669-681.
Read now
Read now
Alexei Gonzalez-Estrada, Keerthi Reddy, Ves Dimov & Frank Eidelman. (2017) Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opinion on Pharmacotherapy 18:11, pages 1137-1143.
Read now
Read now
Articles from other publishers (13)
Juliane R. Santos, Lóide O. Sallum, Marianna C. Silva, Antônio S.N. Aguiar, José L.R. Martins, Pal Perjesi, Ademir J. Camargo & Hamilton B. Napolitano. (2023) Molecular modeling and solubility of olopatadine hydrochloride polymorphs. Computational and Theoretical Chemistry 1224, pages 114110.
Crossref
Crossref
Bill Cavanagh, Paul J. Gomes, Christopher E. Starr, Kelly K. Nichols & Todd C. Brady. (2022) Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial. Ophthalmology and Therapy 11:4, pages 1449-1461.
Crossref
Crossref
David Clark, Bill Cavanagh, Alan L. Shields, Paul Karpecki, John Sheppard & Todd C. Brady. (2021) Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial. American Journal of Ophthalmology 230, pages 60-67.
Crossref
Crossref
Cemal ÇavdarliPınar Topcu Yilmaz. (2020) Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study. Journal of Ocular Pharmacology and Therapeutics 36:7, pages 540-544.
Crossref
Crossref
Hiroaki Ogawa, Tadashi Nakaji-Hirabayashi, Kazuaki Matsumura, Chiaki Yoshikawa, Hiromi Kitano & Yoshiyuki Saruwatari. (2020) Novel anti-biofouling and drug releasing materials for contact lenses. Colloids and Surfaces B: Biointerfaces 189, pages 110859.
Crossref
Crossref
William W. Binotti, Betul Bayraktutar, M. Cuneyt Ozmen, Stephanie M. Cox & Pedram Hamrah. (2020) A Review of Imaging Biomarkers of the Ocular Surface. Eye & Contact Lens: Science & Clinical Practice 46:2, pages S84-S105.
Crossref
Crossref
Shiyan Cao, Shining Cao, Aiwei Chen, Lanlan Yang & Yuan Chen. (2019) Comparing Efficacy and Safety of Olopatadine and Emedastine in
Patients with Allergic Conjunctivitis. International Journal of Pharmacology 15:3, pages 327-335.
Crossref
Crossref
Anne-Nele Grzella, Sabine Schleicher, Kija Shah-Hosseini, Anatoli Astvatsatourov, Esther Raskopf, Silke Allekotte & Ralph Mösges. (2019) Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing. International Archives of Allergy and Immunology 179:2, pages 123-131.
Crossref
Crossref
Hakika Erdogan & Ozlem Cam. (2018) The Effect Of Topical Antihistamines Used Single Dose Daily in Allergic Conjunctivitis. The Open Ophthalmology Journal 12:1, pages 330-337.
Crossref
Crossref
Xuegu Xu & Yonghao Cai. (2018) Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis. Experimental and Therapeutic Medicine.
Crossref
Crossref
Matthew L. Fidler, Abayomi Ogundele, David Covert & Ramesh Sarangapani. (2018) Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%. Journal of Pharmacokinetics and Pharmacodynamics 45:4, pages 593-605.
Crossref
Crossref
Bengi Ece Kurtul, Emrah Utku Kabatas, Songul Deniz Boybeyi, Ayla Akca Caglar & Pinar Altiaylik Ozer. (2017) Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. International Ophthalmology 38:3, pages 1079-1084.
Crossref
Crossref
Warner Carr, Jack Schaeffer & Eric Donnenfeld. (2016) Treating Allergic Conjunctivitis: A Once-daily Medication that Provides 24-hour Symptom Relief. Allergy & Rhinology 7:2, pages ar.2016.7.0158.
Crossref
Crossref